Add this topic to your myFT Digest for news straight to your inbox
Doubts hang over acquisitions struck when the industry was in the grip of an M&A frenzy
It is better to be cheap than stupid
All mid-sized biotechs get bought eventually
US biotech group scouts for drugs ‘complementary’ to liver diseases after hepatitis C successes
Progress shows why big drug companies are good things
New drugs to combat the disease are a boost for the industry but treatment costs are causing controversy
A new drug could be the remedy that has eluded scientists and pharma for more than 20 years. Sam Knight reports
It has other products in its pipeline to go along with one that dominates the market
S&P falls below 1,200 level
Acquisition has considerable advantages in spite of its mind-boggling price
International Edition